Literature DB >> 22943618

Applications of accelerator MS in pediatric drug evaluation.

L T Vuong1, A B Blood, J S Vogel, M E Anderson, B Goldstein.   

Abstract

Accelerator MS (AMS) provides a novel method for obtaining and analyzing pharmacokinetics and pharmacodynamics in children. This paper reviews the scientific and ethical rationale for AMS in pediatric trials, the regulatory framework and general considerations with some specific examples of pediatric clinical trials using AMS. Microdosing in the context of this article refers to studies using a negligible amount (nanocuries) of (14)C as tracer, and AMS as a quantitative technique. The technology is by no means a panacea for the deficiency in pediatric clinical research; however, it lessens the challenges and provides the most quantitative tool for pediatric pharmacology studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22943618     DOI: 10.4155/bio.12.173

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  14 in total

Review 1.  Phase 0/microdosing approaches: time for mainstream application in drug development?

Authors:  Tal Burt; Graeme Young; Wooin Lee; Hiroyuki Kusuhara; Oliver Langer; Malcolm Rowland; Yuichi Sugiyama
Journal:  Nat Rev Drug Discov       Date:  2020-09-08       Impact factor: 84.694

Review 2.  Ethics of drug research in the pediatric intensive care unit.

Authors:  Niina Kleiber; Krista Tromp; Miriam G Mooij; Suzanne van de Vathorst; Dick Tibboel; Saskia N de Wildt
Journal:  Paediatr Drugs       Date:  2015-02       Impact factor: 3.022

Review 3.  Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group.

Authors:  K L R Brouwer; L M Aleksunes; B Brandys; G P Giacoia; G Knipp; V Lukacova; B Meibohm; S K Nigam; M Rieder; S N de Wildt
Journal:  Clin Pharmacol Ther       Date:  2015-09       Impact factor: 6.875

Review 4.  Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology.

Authors:  Heather A Enright; Michael A Malfatti; Maike Zimmermann; Ted Ognibene; Paul Henderson; Kenneth W Turteltaub
Journal:  Chem Res Toxicol       Date:  2016-10-11       Impact factor: 3.739

Review 5.  Microdosing and drug development: past, present and future.

Authors:  Graham Lappin; Robert Noveck; Tal Burt
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-04-04       Impact factor: 4.481

Review 6.  Opportunities in low-level radiocarbon microtracing: applications and new technology.

Authors:  Le Thuy Vuong; Qi Song; Hee Joo Lee; Ad F Roffel; Seok-Ho Shin; Young G Shin; Stephen R Dueker
Journal:  Future Sci OA       Date:  2015-12-23

7.  Successful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism.

Authors:  Miriam G Mooij; Esther van Duijn; Catherijne A J Knibbe; Karel Allegaert; Albert D Windhorst; Joost van Rosmalen; N Harry Hendrikse; Dick Tibboel; Wouter H J Vaes; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2017-10       Impact factor: 6.447

Review 8.  Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development.

Authors:  T Burt; K Yoshida; G Lappin; L Vuong; C John; S N de Wildt; Y Sugiyama; M Rowland
Journal:  Clin Transl Sci       Date:  2016-03-30       Impact factor: 4.689

9.  Dose-linearity of the pharmacokinetics of an intravenous [14 C]midazolam microdose in children.

Authors:  Bianca D van Groen; Wouter H Vaes; B Kevin Park; Elke H J Krekels; Esther van Duijn; Lenne-Triin Kõrgvee; Wioleta Maruszak; Grzegorz Grynkiewicz; R Colin Garner; Catherijne A J Knibbe; Dick Tibboel; Saskia N de Wildt; Mark A Turner
Journal:  Br J Clin Pharmacol       Date:  2019-07-30       Impact factor: 4.335

10.  Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept.

Authors:  Miriam G Mooij; Esther van Duijn; Catherijne A J Knibbe; Albert D Windhorst; N Harry Hendrikse; Wouter H J Vaes; Edwin Spaans; Babs O Fabriek; Hugo Sandman; Dimitri Grossouw; Lidwien M Hanff; Paul J J M Janssen; Birgit C P Koch; Dick Tibboel; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.